Full-Time

Associate Product Manager

Eos

Posted on 9/12/2026

Alphatec Spine

Alphatec Spine

1,001-5,000 employees

Develops and markets spinal surgery solutions

Compensation Overview

$75k - $95k/yr

No H1B Sponsorship

Carlsbad, CA, USA

In Person

Travel up to 40% required.

Bachelor's, Master's, MBA

Category
Product (1)
Required Skills
Forecasting
Product Management
Word/Pages/Docs
Marketing
Excel/Numbers/Sheets

Get referred to Alphatec Spine

See people who can refer or advise you

Requirements
  • A bachelor's degree in Marketing, Business, Life Sciences, Engineering, or a related field is required.
  • At least 3 years of related experience is required, preferably in the medical device industry, or an equivalent combination of education and experience.
  • Ability to develop clear sales tools, training materials, presentations, customer resources, and internal communications.
  • Strong communication, interpersonal, organizational, and project management skills.
  • Ability to collect, synthesize, and communicate field, surgeon, and customer feedback to support product and commercial priorities.
  • Strong attention to detail and ability to manage multiple priorities in a fast-paced, matrixed environment.
  • Proficiency with Microsoft Word, Excel, PowerPoint, artificial intelligence tools, and related business applications is required.
  • Candidates must be authorized to work in the United States without current or future employer sponsorship.
  • For roles requiring access to hospital facilities, candidates must be eligible for and maintain required hospital credentials, including applicable physical and vaccination requirements.
Responsibilities
  • Develop and maintain EOS sales training tools, field-facing materials, onboarding resources, webinars, and related support content to improve sales readiness and consistency.
  • Support EOS sales enablement initiatives, including outreach materials, account targeting support, customer demonstrations, webinars, and follow-up activities that advance commercial opportunities.
  • Coordinate with Medical Education, Surgeon Education, and Sales Training to support EOS course content, training events, and surgeon or sales education programs.
  • Support EOS key opinion leader engagement, peer-to-peer programs, market development events, new key opinion leader onboarding, and ongoing customer engagement activities.
  • Support Insight Council initiatives, including annual meeting coordination, registry growth initiatives, follow-up planning, and ongoing council engagement.
  • Manage EOSedge complaint and feedback intake processes in support of quality management system requirements, partnering with field teams and cross-functional stakeholders to document and communicate product feedback.
  • Translate field, surgeon, and customer feedback into product management inputs, marketing needs, launch support, and product improvement opportunities.
  • Contribute to EOS product management and downstream marketing activities, including competitive tracking, sales collateral, customer resources, forecast inputs, event support, and internal communications.
  • Build working relationships with field sales, sales leadership, surgeon customers, key opinion leaders, consulting physicians, and internal cross-functional partners.
  • Represent EOS at internal meetings, customer-facing activities, sales events, trainings, trade shows, conventions, and other business functions.
  • Travel up to 40%.
Desired Qualifications
  • Medical device industry experience, preferably in spine, orthopedics, imaging, enabling technology, or capital equipment.
  • Experience in field sales, sales training, downstream marketing, product management, or commercial enablement.
  • An MBA or advanced degree.

Alphatec Spine develops and sells implants, instruments, and integrated technologies for spine surgery, including devices used in fusion procedures and related navigation or imaging systems gained through acquisitions like SafeOp Surgical. During surgery, surgeons use these implants and instruments, often with imaging or navigation tools to plan and guide the procedure, while the implants support fusion and healing. It differentiates itself with a broad product portfolio and enhanced technology through strategic acquisitions, giving it capabilities in navigation and advanced spine solutions beyond a narrow line of implants. Its goal is to improve spinal surgery outcomes and expand access to effective spine-care solutions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Carlsbad, California

Founded

1990

Get referred to Alphatec Spine

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $214 million, up 15%, with surgical revenue up 17%.
  • Adjusted EBITDA jumped 53% to $36 million, lifting margin to 17%.
  • The new $300 million credit facility cuts annual interest expense over $6 million.

What critics are saying

  • EOS revenue fell to $14 million in Q1 2026, forcing guidance down to $77 million.
  • Kirby McInerney and Ademi investigated May 2026 disclosures after the 32% stock drop.
  • A prolonged EOS failure plus litigation can choke refinancing and trigger a dilution spiral.

What makes Alphatec Spine unique

  • Alphatec’s EOS imaging and SafeOp bundle intraoperative planning, navigation, and neuro-monitoring.
  • Patrick Miles built a surgeon-adoption playbook, adding 24% net new surgeons in Q2 2026.
  • U.S.-centric direct-sales execution keeps Alphatec close to hospital buying committees.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Sick Leave

Paid Holidays

Disability Insurance

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

4%

2 year growth

4%
Yahoo Finance
Sep 14th, 2026
Alphatec surges 19.7% on Q2 results, expects $882M revenue for 2026

Alphatec shares surged 19.7% to $10.58, driven by investor optimism following strong second-quarter 2026 results. The medical equipment company reported earnings per share of 7 cents and revenues of $213.5 million for the quarter. The company maintains its full-year 2026 revenue guidance of approximately $882 million, supported by strong case volume growth, increased surgeon adoption, expanding profitability and positive free cash flow generation. For the upcoming quarter, Alphatec expects earnings of $0.11 per share, representing a 266.7% year-over-year increase. Revenues are projected at $224.28 million, up 14.1% from the prior year. However, the consensus earnings estimate has remained unchanged over the past 30 days. The stock currently carries a Zacks Rank #3 (Hold).

Yahoo Finance
Aug 5th, 2026
Alphatec delivers $214M revenue and 53% adjusted EBITDA growth despite biologics headwinds

Alphatec Holdings reported strong Q2 2026 results with total revenue of $214 million, up 15% year-over-year, and surgical revenue of $196 million, up 17%. The medical device company saw adjusted EBITDA rise 53% to $36 million, with margins expanding 420 basis points to 17%. The company added 24% more net new surgeons and posted 20% case volume growth. Gross margin improved 260 basis points to 72.5%, driven by better inventory efficiency and favourable product mix. Alphatec generated positive free cash flow of approximately $1 million in Q2 and raised full-year adjusted EBITDA guidance to $140 million from $134 million previously. However, revenue per case declined 2.7% due to case mix shifts and international growth. The company now expects full-year revenue per case to decline in the low single digits, citing slower biologics attachment improvement.

Yahoo Finance
Jun 11th, 2026
Alphatec grows revenue 25% to $764M but posts $143M loss with 17.2x debt-to-equity ratio

Alphatec, a spine surgery technology company, reported revenue of $764.2 million in FY 2025, up 25% year-over-year, but posted a net loss of $143.4 million. The company's debt-to-equity ratio stands at approximately 17.2x, whilst its current ratio is 2.1x. Stock-based compensation represented roughly 163% of operating cash flow. Inspire Medical Systems specialises in neurostimulation therapy for obstructive sleep apnea patients who cannot use standard breathing machines. The company targets sleep specialists and ENT surgeons globally. Alphatec differentiates itself through an integrated ecosystem using subsidiaries like EOS imaging and SafeOp Surgical, serving primarily the US hospital market whilst expanding into Europe and Japan. Both companies operate in medical technology but represent different maturity levels and financial profiles for investors seeking healthcare device exposure.

Yahoo Finance
Jun 1st, 2026
Alphatec posts 17% surgical revenue growth, cuts interest expenses by $6M with new bank facility

Alphatec Holdings, a medical technology company specialising in spinal surgery solutions, reported strong first-quarter 2026 results with surgical revenue up 17% and total revenue growing 14% to $192 million. The company achieved non-GAAP adjusted EBITDA of $21 million whilst securing a new bank facility that reduces annual interest expenses by over $6 million. Growth was driven by a 21% increase in surgical case volume and 23% rise in net new surgeon users. The company reported an ending cash balance of $140 million and trailing twelve-month free cash flow of $7 million. For full-year 2026, Alphatec expects total revenue of approximately $882 million, representing 15% growth, with adjusted EBITDA projected at $134 million and at least $20 million in free cash flow generation.

Business Wire
May 19th, 2026
Law firm investigates Alphatec after shares plunge 32% on missed EOS revenue guidance

Kirby McInerney LLP is investigating potential securities law violations by Alphatec Holdings and its senior management following a sharp share price decline. On 5 May 2026, Alphatec reported first quarter revenue of $192 million and disclosed that EOS revenue, from its proprietary imaging platform, was $14 million—below internal expectations. The company reduced its full-year 2026 EOS revenue guidance to approximately $77 million from $85 million, citing execution issues with equipment installations. Management stated that "installation timing was a challenge" and the company failed to fulfill committed units. Following the announcement, Alphatec shares fell 32%, from $10.23 to $6.99 per share. No lawsuit has been filed yet, and the investigation is ongoing to determine whether claims may be brought under federal securities laws.